Athira Pharma

Restoring lives by advancing bold therapies for neuronal health, thoughtfully and urgently

General Information
Company Name
Athira Pharma
Founded Year
2011
Location (Offices)
Bothell, United States +1
Founders / Decision Makers
Joseph Harding - Chief Scientific Officer Andrew Gengos - Chief Financial Officer and Chief Business Officer Rachel Lenington - Chief Operating Officer Kevin Church - Chief Scientific Officer Mark Litton - President & Chief Executive Officer Kelly Romano - Independent Director - Board of Directors Javier San Martin - Chief Medical Officer
Number of Employees
46
Industries
Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage
Post Ipo Equity
Social Media

Athira Pharma - Company Profile

Athira Pharma is a biotechnology and pharmaceutical company headquartered in the United States, founded in 2011. The company's slogan, "Restoring lives by advancing bold therapies for neuronal health, thoughtfully and urgently," reflects its mission to restore neuronal health for those suffering from neurological diseases such as Alzheimer’s, Parkinson’s disease dementia, and dementia with Lewy bodies. Athira Pharma's latest milestone includes a $103.50M post-IPO equity investment on 20 January 2021, signaling confidence in the company's approach. The company is driven by a motivated, impassioned team committed to making a positive impact on human health.

Taxonomy: neuronal health, therapies, Alzheimer's, Parkinson's disease, dementia, Lewy bodies, neurological diseases, innovation, pharmaceuticals

Funding Rounds & Investors of Athira Pharma (8)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $103.50M - 20 Jan 2021
Grant $15.00M 1 National Institute on Aging 08 Dec 2020
Convertible Note Unknown 1
Primer Capital, investor in Athira Pharma's Convertible Note round
04 Sep 2020
Series B $85.00M 10
Sofinnova Investments, investor in Athira Pharma's Series B round Perceptive Advisors, investor in Athira Pharma's Series B round Rock Springs Capital, investor in Athira Pharma's Series B round RTW Investments, investor in Athira Pharma's Series B round Sahsen Ventures, investor in Athira Pharma's Series B round Viking Global Investors, investor in Athira Pharma's Series B round Venrock Healthcare Capital Partners, investor in Athira Pharma's Series B round
Suzanne Kayne, Surveyor Capital +1 		04 Jun 2020
Series B $15.20M 7
Outcomes Fund, investor in Athira Pharma's Series B round Dolby Ventures, investor in Athira Pharma's Series B round W Fund, investor in Athira Pharma's Series B round
Michael Montgomery, Kayne Anderson Capital Advisors +2 		02 Nov 2017

View All 8 Funding Rounds

Latest News of Athira Pharma

View All

No recent news or press coverage available for Athira Pharma.

Similar Companies to Athira Pharma

View All
Remo Health - Similar company to Athira Pharma
Remo Health Better dementia care. Delivered virtually.
National Council of Certified Dementia Practitioners (NCCDP) - Similar company to Athira Pharma
National Council of Certified Dementia Practitioners (NCCDP) NCCDP: Offers expert dementia training for healthcare & frontline professionals.
Dementia Training Australia - Similar company to Athira Pharma
Dementia Training Australia Improving the care and wellbeing of people living with dementia and the staff delivering their care
Tembo Health - Similar company to Athira Pharma
Tembo Health making managing dementia easier
Brain+ - Similar company to Athira Pharma
Brain+ Helping people affected by dementia, live better lives